98 related articles for article (PubMed ID: 15735723)
1. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein.
Fest T; Guffei A; Williams G; Silva S; Mai S
Oncogene; 2005 Apr; 24(18):2944-53. PubMed ID: 15735723
[TBL] [Abstract][Full Text] [Related]
2. Telomeric aggregates and end-to-end chromosomal fusions require myc box II.
Caporali A; Wark L; Vermolen BJ; Garini Y; Mai S
Oncogene; 2007 Mar; 26(10):1398-406. PubMed ID: 16953226
[TBL] [Abstract][Full Text] [Related]
3. c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis.
Fest T; Mougey V; Dalstein V; Hagerty M; Milette D; Silva S; Mai S
Oncogene; 2002 May; 21(19):2981-90. PubMed ID: 12082528
[TBL] [Abstract][Full Text] [Related]
4. PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease.
Matis S; Mariani MR; Cutrona G; Cilli M; Piccardi F; Daga A; Damonte G; Millo E; Moroni M; Roncella S; Fedeli F; Boffa LC; Ferrarini M
Cancer Gene Ther; 2009 Oct; 16(10):786-93. PubMed ID: 19363465
[TBL] [Abstract][Full Text] [Related]
5. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
6. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
7. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
8. Lack of mutagenicity and clastogenicity of PNAEmu-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma.
Boffa LC; Menichini P; Bolognesi C; Cutrona G; Roncella S; Damonte GL; Millo E; Mariani MR; Matis S; Russo D; Ciliutti P; Ferrarini M
Mutat Res; 2007 Apr; 628(2):129-37. PubMed ID: 17267263
[TBL] [Abstract][Full Text] [Related]
9. Gene-hypermutated isoforms of MYC protein: Tumour-suppressor P-53 protective-initiation of apoptosis that normally prevents Burkitt's lymphoma tumorigenesis can be enhanced.
Wiseman A
Med Hypotheses; 2006; 66(5):1046-7. PubMed ID: 16413684
[No Abstract] [Full Text] [Related]
10. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
12. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.
Boffa LC; Cutrona G; Cilli M; Matis S; Damonte G; Mariani MR; Millo E; Moroni M; Roncella S; Fedeli F; Ferrarini M
Cancer Gene Ther; 2007 Feb; 14(2):220-6. PubMed ID: 17053816
[TBL] [Abstract][Full Text] [Related]
14. c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli.
Kuttler F; Amé P; Clark H; Haughey C; Mougin C; Cahn JY; Dang CV; Raffeld M; Fest T
Oncogene; 2001 Sep; 20(42):6084-94. PubMed ID: 11593416
[TBL] [Abstract][Full Text] [Related]
15. Elevated presence of retrotransposons at sites of DNA double strand break repair in mouse models of metabolic oxidative stress and MYC-induced lymphoma.
Rockwood LD; Felix K; Janz S
Mutat Res; 2004 Apr; 548(1-2):117-25. PubMed ID: 15063142
[TBL] [Abstract][Full Text] [Related]
16. c-myc Suppression in Burkitt's lymphoma cells.
Simonsson T; Henriksson M
Biochem Biophys Res Commun; 2002 Jan; 290(1):11-5. PubMed ID: 11779125
[TBL] [Abstract][Full Text] [Related]
17. Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations.
Rockwood LD; Torrey TA; Kim JS; Coleman AE; Kovalchuk AL; Xiang S; Ried T; Morse HC; Janz S
Oncogene; 2002 Oct; 21(47):7235-40. PubMed ID: 12370814
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
19. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma.
Boffa LC; Cutrona G; Cilli M; Mariani MR; Matis S; Pastorino M; Damonte G; Millo E; Roncella S; Ferrarini M
Oligonucleotides; 2005; 15(2):85-93. PubMed ID: 15989423
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
